Haematologica (May 2011)

MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia

  • Diana Schotte,
  • Renée X. De Menezes,
  • Farhad Akbari Moqadam,
  • Leila Mohammadi Khankahdani,
  • Ellen Lange-Turenhout,
  • Caifu Chen,
  • Rob Pieters,
  • Monique L. Den Boer

DOI
https://doi.org/10.3324/haematol.2010.026138
Journal volume & issue
Vol. 96, no. 5

Abstract

Read online

Background MicroRNA regulate the activity of protein-coding genes including those involved in hematopoietic cancers. The aim of the current study was to explore which microRNA are unique for seven different subtypes of pediatric acute lymphoblastic leukemia.Design and Methods Expression levels of 397 microRNA (including novel microRNA) were measured by quantitative real-time polymerase chain reaction in 81 cases of pediatric leukemia and 17 normal hematopoietic control cases.Results All major subtypes of acute lymphoblastic leukemia, i.e. T-cell, MLL-rearranged, TEL-AML1-positive, E2A-PBX1-positive and hyperdiploid acute lymphoblastic leukemia, with the exception of BCR-ABL-positive and ‘B-other’ acute lymphoblastic leukemias (defined as precursor B-cell acute lymphoblastic leukemia not carrying the foregoing cytogenetic aberrations), were found to have unique microRNA-signatures that differed from each other and from those of healthy hematopoietic cells. Strikingly, the microRNA signature of TEL-AML1-positive and hyperdiploid cases partly overlapped, which may suggest a common underlying biology. Moreover, aberrant down-regulation of let-7b (~70-fold) in MLL-rearranged acute lymphoblastic leukemia was linked to up-regulation of oncoprotein c-Myc (PFDR